Frontiers in Neurology (Jun 2024)

Dyskinetic crisis in GNAO1-related disorders: clinical perspectives and management strategies

  • Jana Domínguez Carral,
  • Carola Reinhard,
  • Carola Reinhard,
  • Darius Ebrahimi-Fakhari,
  • Nathalie Dorison,
  • Serena Galosi,
  • Giacomo Garone,
  • Giacomo Garone,
  • Masa Malenica,
  • Claudia Ravelli,
  • Esra Serdaroglu,
  • Laura A. van de Pol,
  • Laura A. van de Pol,
  • Anne Koy,
  • Vincenzo Leuzzi,
  • Agathe Roubertie,
  • Jean-Pierre Lin,
  • Jean-Pierre Lin,
  • Diane Doummar,
  • Laura Cif,
  • Laura Cif,
  • Laura Cif,
  • Juan Darío Ortigoza-Escobar,
  • Juan Darío Ortigoza-Escobar,
  • Juan Darío Ortigoza-Escobar

DOI
https://doi.org/10.3389/fneur.2024.1403815
Journal volume & issue
Vol. 15

Abstract

Read online

BackgroundGNAO1-related disorders (GNAO1-RD) encompass a diverse spectrum of neurodevelopmental and movement disorders arising from variants in the GNAO1 gene. Dyskinetic crises, marked by sudden and intense exacerbations of abnormal involuntary movements, present a significant challenge in GNAO1-RD.ObjectivesThis study aimed to establish a standardized framework for understanding dyskinetic crises, addressing crucial aspects such as definition, triggers, diagnostic criteria, complications, and management strategies.MethodsA Delphi consensus process was conducted involving international experts in GNAO1-RD. The panel of thirteen experts participated in three voting rounds, discussing 90 statements generated through a literature review and clinical expertise.ResultsConsensus was achieved on 31 statements, defining dyskinetic crises as abrupt, paroxysmal episodes involving distinct abnormal movements in multiple body regions, triggered by emotional stress or infections. Dyskinetic crises may lead to functional impairment and complications, emphasizing the need for prompt recognition. While individualized pharmacological recommendations were not provided, benzodiazepines and clonidine were suggested for acute crisis management. Chronic treatment options included tetrabenazine, benzodiazepines, gabapentin, and clonidine. Deep brain stimulation should be considered early in the treatment of refractory or prolonged dyskinetic crisis.ConclusionThis consensus provides a foundation for understanding and managing dyskinetic crises in GNAO1-RD for clinicians, caregivers, and researchers. The study emphasizes the importance of targeted parental and caregiver education, which enables early recognition and intervention, thereby potentially minimizing both short- and long-term complications. Future research should concentrate on differentiating dyskinetic crises from other neurological events and investigating potential risk factors that influence their occurrence and nature. The proposed standardized framework improves clinical management, stakeholder communication, and future GNAO1-RD research.

Keywords